Treatment of Small Cell Lung Cancer Diagnosis and Management of Lung Cancer , 3 rd ed : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
暂无分享,去创建一个
[1] J. Walters,et al. Platinum versus non-platinum chemotherapy regimens for small cell lung cancer. , 2015, The Cochrane database of systematic reviews.
[2] G. Michaud,et al. Symptom management in patients with lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. , 2013, Chest.
[3] E. Vokes,et al. Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] T. Gauler,et al. A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] K. Nackaerts,et al. Randomized phase III trial of amrubicin versus topotecan (Topo) as second-line treatment for small cell lung cancer (SCLC). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] N. Saijo,et al. Common arm comparative outcomes analysis of phase 3 trials of cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer: final patient-level results from Japan Clinical Oncology Group 9511 and Southwest Oncology Group 0124. , 2010, Cancer.
[7] A. Sasse,et al. Camptothecins Compared with Etoposide in Combination with Platinum Analog in Extensive Stage Small Cell Lung Cancer: Systematic Review with Meta-Analysis , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[8] J. Soria,et al. A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] A. Scott,et al. High Impact of 18F-FDG-PET on Management and Prognostic Stratification of Newly Diagnosed Small Cell Lung Cancer , 2010, Molecular Imaging and Biology.
[10] M. Rotman,et al. Survival outcomes with the use of surgery in limited‐stage small cell lung cancer , 2010, Cancer.
[11] L. Wilson,et al. Surveillance Epidemiology and End Results Evaluation of the Role of Surgery for Stage I Small Cell Lung Cancer , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[12] D. Moore,et al. Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] A. Hackshaw,et al. Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial. , 2009, Journal of the National Cancer Institute.
[14] J. Hainsworth,et al. Phase II Trial of Irinotecan, Carboplatin, and Bevacizumab in the Treatment of Patients with Extensive-Stage Small-Cell Lung Cancer , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[15] J. Crowley,et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] Y. Nishiyama,et al. Early Assessment of Therapeutic Response using FDG PET in Small Cell Lung Cancer , 2009, Molecular Imaging and Biology.
[17] M. Yun,et al. High Tumor Metabolic Activity as Measured by Fluorodeoxyglucose Positron Emission Tomography Is Associated with Poor Prognosis in Limited and Extensive Stage Small-Cell Lung Cancer , 2009, Clinical Cancer Research.
[18] J. Zell,et al. The Applicability of the Proposed IASLC Staging Revisions to Small Cell Lung Cancer (SCLC) with Comparison to the Current UICC 6th TNM Edition , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[19] M. Suntharalingam,et al. Evaluation of the use of prophylactic cranial irradiation in small cell lung cancer , 2009, Cancer.
[20] F. Hommura,et al. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] L. Ek,et al. Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] C. Faivre-Finn,et al. Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer , 2008, British Journal of Cancer.
[23] E. Smit,et al. Phase III study of cyclophosphamide, doxorubicin, and etoposide compared with carboplatin and paclitaxel in patients with extensive disease small-cell lung cancer. , 2007, European journal of cancer.
[24] A. Turrisi,et al. Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). , 2007, Chest.
[25] J. Pujol,et al. Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] L. Collette,et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. , 2007, The New England journal of medicine.
[27] S. Hillman,et al. Results of a phase II study of high-dose thoracic radiation therapy with concurrent cisplatin and etoposide in limited-stage small-cell lung cancer (NCCTG 95-20-53). , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] N. Saijo,et al. Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702 , 2007, British Journal of Cancer.
[29] J. von Pawel,et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] T. Ciuleanu,et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] H. Hansen,et al. A prospective study of PET/CT in initial staging of small-cell lung cancer: comparison with CT, bone scintigraphy and bone marrow analysis. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[32] C. Obasaju,et al. Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] H. Hansen,et al. PET/CT imaging in response evaluation of patients with small cell lung cancer. , 2006, Lung cancer.
[34] N. Hanna,et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] A. Twijnstra,et al. Response of asymptomatic brain metastases from small-cell lung cancer to systemic first-line chemotherapy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] R. Marks,et al. Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. , 2005, Journal of Clinical Oncology.
[37] J. Jett,et al. Results of combined‐modality therapy for limited‐stage small cell lung carcinoma in the elderly , 2005, Cancer.
[38] C. Tibaldi,et al. Platinum-etoposide chemotherapy in elderly patients with small-cell lung cancer: results of a randomized multicenter phase II study assessing attenuated-dose or full-dose with lenograstim prophylaxis--a Forza Operativa Nazionale Italiana Carcinoma Polmonare and Gruppo Studio Tumori Polmonari Veneto , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] M. Socinski,et al. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] 谷澤 豊,et al. 膵臓癌切除後再発に対する, Fluorine-18-2-fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) の有用性の検討 , 2004 .
[41] Jeffrey D Bradley,et al. Positron emission tomography in limited-stage small-cell lung cancer: a prospective study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] E. Stoelben,et al. Impact of [18F]FDG-PET on the primary staging of small-cell lung cancer , 2004, European Journal of Nuclear Medicine and Molecular Imaging.
[43] R. Arusell,et al. Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer. , 2004, International journal of radiation oncology, biology, physics.
[44] D. Ball,et al. Impact of Positron Emission Tomography on the Management of Patients With Small-Cell Lung Cancer: Preliminary Experience , 2004, American journal of clinical oncology.
[45] J. Hengstler,et al. Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer--what limits limited disease? , 2002, Lung cancer.
[46] J. Lafitte,et al. A phase II randomised trial comparing the cisplatin-etoposide combination chemotherapy with or without carboplatin as second-line therapy for small-cell lung cancer. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[47] L. Adler,et al. Whole body FDG-PET for the evaluation and staging of small cell lung cancer: a preliminary study. , 2002, Lung cancer.
[48] K. Mori,et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. , 2002, The New England journal of medicine.
[49] M. Mix,et al. FDG-PET imaging for the staging and follow-up of small cell lung cancer , 2001, European Journal of Nuclear Medicine.
[50] M. Ranson,et al. Phase ii comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] A. Pforte,et al. Positron emission tomography in the staging of small-cell lung cancer : a preliminary study. , 2001, Chest.
[52] M. Inoue,et al. Results of preoperative mediastinoscopy for small cell lung cancer. , 2000, The Annals of thoracic surgery.
[53] R. Livingston,et al. Similar outcome of elderly patients in intergroup trial 0096: Cisplatin, etoposide, and thoracic radiotherapy administered once or twice daily in limited stage small cell lung carcinoma. , 2000, Cancer.
[54] A. Twijnstra,et al. Asymptomatic Brain Metastases (BM) in Small Cell Lung Cancer (SCLC): MR-imaging is Useful at Initial Diagnosis , 2000, Journal of Neuro-Oncology.
[55] B. Jeremic,et al. Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: A randomized study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[56] R. Komaki,et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. , 1999, The New England journal of medicine.
[57] T K Lewellen,et al. Carbon-11-thymidine and FDG to measure therapy response. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[58] A. Gregor. Prophylactic cranial irradiation in small-cell lung cancer: is it ever indicated? , 1998, Oncology.
[59] A. Chella,et al. Surgery in the management of small cell lung cancer. , 1997, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[60] R. Souhami,et al. Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy. , 1997, Journal of the National Cancer Institute.
[61] P Chomy,et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. , 1995, Journal of the National Cancer Institute.
[62] J P Pignon,et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. , 1992, The New England journal of medicine.
[63] P. Warde,et al. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[64] R. Ginsberg,et al. Surgical treatment for limited small-cell lung cancer. The University of Toronto Lung Oncology Group experience. , 1991, The Journal of thoracic and cardiovascular surgery.
[65] J. Crowley,et al. Comparison of etoposide and cisplatin with bis‐chloro‐ethylnitrosourea, thiotepa, vincristine, and cyclophosphamide for salvage treatment in small cell lung cancer. A Southwest Oncology Group Study , 1990, Cancer.
[66] R. Ginsberg,et al. Staging and prognostic factors in small cell lung cancer: a consensus report , 1989 .
[67] M. Partridge,et al. Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. , 1989, British Journal of Cancer.
[68] M. Perry,et al. Bone marrow involvement in small cell lung cancer. Clinical significance and correlation with routine laboratory variables , 1989, Cancer.
[69] T. Shields,et al. The importance of surgical and multimodality treatment for small cell bronchial carcinoma. , 1989, The Journal of thoracic and cardiovascular surgery.
[70] E. Shaw,et al. Leukoencephalopathy in Small Cell Lung Cancer Patients Receiving Prophylactic Cranial Irradiation , 1989, American journal of clinical oncology.
[71] G. Giaccone,et al. Reinduction chemotherapy in small cell lung cancer. , 1987, European journal of cancer & clinical oncology.
[72] P. Postmus,et al. Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy. , 1987, European journal of cancer & clinical oncology.
[73] G. Kalemkerian,et al. Small cell lung cancer , 2010, Seminars in Respiratory and Critical Care Medicine.
[74] G. Deboer,et al. Is bone marrow examination in small-cell lung cancer really necessary? , 1986, Annals of internal medicine.
[75] F. Greco,et al. Randomized dose-response evaluation of etoposide in small cell carcinoma of the lung: a Southeastern Cancer Study Group Trial. , 1986, Cancer treatment reports.
[76] H. Hansen,et al. Influence of surgical resection prior to chemotherapy on the long-term results in small cell lung cancer. A study of 150 operable patients. , 1986, European journal of cancer & clinical oncology.
[77] D. Greschuchna,et al. Small Cell Carcinoma of the Lung - to Operate or not? Surgical Experience and Results , 1986, The Thoracic and cardiovascular surgeon.
[78] G. Mickisch,et al. Surgical Resection and Adjuvant Chemotherapy for Small Cell Carcinoma , 1986, The Thoracic and cardiovascular surgeon.
[79] R. Makuch,et al. Neurologic, neuropsychologic, and computed cranial tomography scan abnormalities in 2- to 10-year survivors of small-cell lung cancer. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[80] L. Faling,et al. The value of the bone scan and bone marrow biopsy in staging small cell lung cancer , 1985, Cancer.
[81] M. Troxell,et al. Effect of initial resection of small-cell carcinoma of the lung: a review of Southwest Oncology Group Study 7628. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[82] J. Tepper,et al. Follow-up neurological evaluation in patients with small cell lung carcinoma treated with prophylactic cranial irradiation and chemotherapy. , 1979, International journal of radiation oncology, biology, physics.
[83] M. Zelen. Keynote address on biostatistics and data retrieval. , 1973, Cancer chemotherapy reports. Part 3.
[84] N. D’Esopo,et al. Controlled study of survival of patients with clinically inoperable lung cancer treated with radiation therapy. , 1966, The American journal of medicine.
[85] Andrew Bottomley,et al. Prophylactic cranial irradiation in extensive disease small-cell lung cancer: short-term health-related quality of life and patient reported symptoms: results of an international Phase III randomized controlled trial by the EORTC Radiation Oncology and Lung Cancer Groups. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[86] L. Tanoue,et al. The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumors , 2009 .
[87] A. Rapti,et al. Comparison of cisplatin-paclitaxel combination versus cisplatin-etoposide in patients with small-cell lung cancer: a Phase III study. , 2008, Oncology reports.
[88] N. Gupta,et al. Can positron emission tomography be used as a staging tool for small-cell lung cancer? , 2008, Clinical lung cancer.
[89] H. Ohmatsu,et al. Detection of unsuspected distant metastases and/or regional nodes by FDG-PET [corrected] scan in apparent limited-disease small-cell lung cancer. , 2007, Lung cancer.
[90] Matthias T Wyss,et al. Whole-body (18)F-FDG PET improves the management of patients with small cell lung cancer. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[91] S. Larson,et al. Prognostic value of [18F]FDG-PET imaging in small cell lung cancer , 2002, European Journal of Nuclear Medicine and Molecular Imaging.
[92] A. Szczesna,et al. [Surgical treatment of limited small cell lung cancer]. , 2001, Pneumonologia i alergologia polska.
[93] A. Garden,et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. , 2000, International journal of radiation oncology, biology, physics.
[94] E. Smit,et al. Testing the possible non-cross resistance of two equipotent combination chemotherapy regimens against small-cell lung cancer: a phase II study of the EORTC Lung Cancer Cooperative Group. , 1993, European journal of cancer.